Piper Jaffray Upgrades Anadys Pharmaceuticals (ANDS) to Overweight
Tweet Send to a Friend
Piper Jaffray & Co. upgrades Anadys Pharmaceuticals (Nasdaq: ANDS) from Neutral to Overweight. Price target $2.50.
Piper analyst says, "Early ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Piper analyst says, "Early ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
